Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.58 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985244 | 1.00 | EGFR (0.65) | EGFRIRAK4MAP3K7IRAK1HDAC6 | |
| SCHEMBL13500562 | 0.89 | IRAK4 (0.73) | EGFRIRAK4MAP3K7IRAK1ALK | |
| SCHEMBL1925095 | 0.89 | IRAK4 (0.73) | EGFRIRAK4MAP3K7IRAK1ALK | |
| SCHEMBL1925097 | 0.89 | IRAK4 (0.73) | EGFRIRAK4MAP3K7IRAK1ALK | |
| SCHEMBL20985404 | 0.89 | EGFR (0.68) | EGFRIRAK4MAP3K7IRAK1 | |
| SCHEMBL20985403 | 0.89 | EGFR (0.68) | EGFRIRAK4MAP3K7IRAK1 | |
| SCHEMBL29937318 | 0.88 | EGFR (0.64) | EGFRIRAK4MAP3K7IRAK1HDAC6 | |
| SCHEMBL21026258 | 0.88 | EGFR (0.64) | EGFRIRAK4MAP3K7IRAK1HDAC6 | |
| SCHEMBL20985425 | 0.86 | IRAK4 (0.72) | EGFRIRAK4MAP3K7IRAK1 | |
| SCHEMBL20985426 | 0.86 | IRAK4 (0.72) | EGFRIRAK4MAP3K7IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | EGFR 268/4885IRAK4 2/4885MAP3K7 536/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 349/4885IRAK4 2/4885MAP3K7 533/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 268/4885IRAK4 2/4885MAP3K7 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.